Search

Displaying results 2961 - 2970 of 10000 in total
  1. Drug

    Umbralisib

    go.drugbank.com/drugs/DB14989
    ApprovedInvestigationalWithdrawn

    While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated … Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy.

  2. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    [A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  3. Drug

    Amibegron

    go.drugbank.com/drugs/DB05395
    Investigational

    Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

  4. Drug

    Boron

    go.drugbank.com/drugs/DB11203
    ApprovedInvestigational

    Natural boron exists in 2 stable isotopes however pure boron is hard to prepare due to contamination by different elements. … additive in glass fibers of boron-containing fiberglass for insulation and structural materials.

    Mixtures: Calcium Folic Acid Plus D Chewable
  5. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as … In comparison to synthetic forms of surfacant, natural forms such as Beractant have been found to have a reduced incidence of pneumothorax and reduced mortality.

  6. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    of cytokine release syndrome (CRS), a serious condition associated with the use of immunotherapy. … [L43887,L43892] A phase I clinical study (NCT02290951) showed that in heavily pre-treated patients with B-cell non-Hodgkin lymphoma, odronextamab elicited a durable response with a manageable safety

  7. Drug

    Pilocarpine

    go.drugbank.com/drugs/DB01085
    ApprovedInvestigational

    A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist. … The usage of glaucoma by pilocarpine dates back to 1875.[A262041]

  8. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell. … Self-amplification allows for the use of lower doses while providing higher immunogenicity compared to a conventional mRNA COVID-19 vaccine.

  9. Drug

    Poractant alfa

    go.drugbank.com/drugs/DB09113
    ApprovedInvestigational

    Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives. … Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B

  10. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion. … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering